Fortress Biotech, Inc. (FBIO) Analysts See $-0.57 EPS

February 20, 2018 - By Rodney Autry

 Fortress Biotech, Inc. (FBIO) Analysts See $ 0.57 EPS

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.57 EPS on March, 15.They anticipate $0.14 EPS change or 32.56 % from last quarter’s $-0.43 EPS. After having $-0.67 EPS previously, Fortress Biotech, Inc.’s analysts see -14.93 % EPS growth. The stock decreased 0.28% or $0.01 during the last trading session, reaching $3.51. About 164,025 shares traded or 34.02% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since February 20, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 2 analysts covering Fortress Biotech (NASDAQ:FBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 7 analyst reports since July 11, 2017 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, July 11. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 12 report. H.C. Wainwright maintained it with “Buy” rating and $11.0 target in Tuesday, December 5 report. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) has “Buy” rating given on Wednesday, September 27 by H.C. Wainwright. The firm has “Buy” rating given on Thursday, August 10 by H.C. Wainwright. As per Tuesday, January 2, the company rating was maintained by H.C. Wainwright.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $177.80 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

More notable recent Fortress Biotech, Inc. (NASDAQ:FBIO) news were published by: Seekingalpha.com which released: “Fortress Biotech: This 9.375% Preferred Stock Started Trading On The NASDAQ” on November 16, 2017, also Globenewswire.com with their article: “Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative …” published on November 08, 2017, Globenewswire.com published: “Fortress Biotech Announces Positive Clinical Data From Fortress Companies …” on December 11, 2017. More interesting news about Fortress Biotech, Inc. (NASDAQ:FBIO) were released by: Globenewswire.com and their article: “Fortress Biotech Announces Proposed Public Offering of Series A Preferred Stock” published on November 01, 2017 as well as Globenewswire.com‘s news article titled: “Fortress Biotech Announces Pricing of Series A Preferred Stock Offering” with publication date: November 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.